1 Min Read
Nov 2 (Reuters) - Quest Pharmatech Inc :
* Oncovent initiates clinical development program for anti-MUC1 MAb AR20.5 for treatment of pancreatic cancer Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.